Eye drops could make fuchs surgery less invasive
NCT ID NCT05275972
First seen Jan 03, 2026 · Last updated Jun 20, 2026 · Updated 22 times
Summary
This study compares two surgical approaches for Fuchs endothelial dystrophy, a condition that clouds the cornea. One is a full corneal transplant (DMEK), the other is a simpler procedure that removes only the diseased cells (DSO) plus Ripasudil eye drops to help healing. 60 participants will be randomly assigned to one of the two treatments. The goal is to see if the simpler surgery with drops can achieve similar vision improvement to the transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FUCHS' ENDOTHELIAL DYSTROPHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dartmouth-Hitchcock Medical Center
RECRUITINGLebanon, New Hampshire, 03766, United States
Contact Email: •••••@•••••
Contact
-
Legacy Devers Eye Institute
RECRUITINGPortland, Oregon, 97210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Oregon Health & Science University
RECRUITINGPortland, Oregon, 97239, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Stanford University
RECRUITINGPalo Alto, California, 94303, United States
Contact
Contact
Contact Email: •••••@•••••
-
University of California Davis
RECRUITINGSacramento, California, 95817, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Miami
RECRUITINGPalm Beach Gardens, Florida, 33418, United States
Contact
Contact Email: •••••@•••••
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Email: •••••@•••••
Contact
-
Wills Eye Hospital
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ripasudil (eye drops)
What this could lead to
If it works, this could offer a less invasive surgical option for Fuchs dystrophy, reducing recovery time and risks while maintaining good vision.
What could go wrong
This is a small, early-phase trial with only 60 participants. The drops may not work as hoped, and the less invasive surgery might not provide lasting vision improvement.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.